Research Articles

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.

Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ, REACT study group, Protocol Steering Committee, Coordinating Centre, Site Principal Investigators

Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.

Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J

Controlling COVID-19 via test-trace-quarantine.

Kerr CC, Mistry D, Stuart RM, Rosenfeld K, Hart GR, Núñez RC, Cohen JA, Selvaraj P, Abeysuriya RG, Jastrzębski M, George L, Hagedorn B, Panovska-Griffiths J, Fagalde M, Duchin J, Famulare M, Klein DJ

COVID-19

The prevalence of uterine fundal pressure during the second stage of labour for women giving birth in health facilities: a systematic review and meta-analysis.

Farrington E, Connolly M, Phung L, Wilson AN, Comrie-Thomson L, Bohren MA, Homer CSE, Vogel JP

The Melbourne Safe Injecting Room Attracted People Most in Need of Its Service.

Van Den Boom W, Del Mar Quiroga M, Fetene DM, Agius PA, Higgs PG, Maher L, Hickman M, Stoové MA, Dietze PM

Performance characteristics of an instrument-free point-of-care CD4 test (VISITECT®CD4) for use in resource-limited settings.

Vidhyavathi V, Iqbal HS, Kanthamani K, Solomon SS, Nandagopal P, Luchters S, Pham MD, Forbes J, Crowe SM, McMurran C, Anderson DA, Balakrishnan P